Glutathione S-transferase M1, T1 status and the risk of head and neck cancer: A meta-analysis

Journal of Medical Genetics

Volumn 41, Issue 5, 2004, Pages 360-365

  Ye, Z ^a   Song, H ^b   Guo, Y ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; GLUTATHIONE TRANSFERASE;

ALCOHOL CONSUMPTION; ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CONJUGATION; DETOXIFICATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENETIC SUSCEPTIBILITY; HEAD CANCER; HUMAN; MAJOR CLINICAL STUDY; METABOLISM; NECK CANCER; PRIORITY JOURNAL; PROTEIN FAMILY; SMOKING; TOBACCO DEPENDENCE;

NICOTIANA TABACUM;

EID: 2342466683     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2003.016246     Document Type: Article

References (59)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. Cloos J, Spitz MR, Schantz SP, Hsu PS, Zhang ZF, Tobi H, Braakhuis BJ, Snow GB. Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:530-5.
3. Khuri FR, Lippman SM, Spitz MR Latan R, Hong WK. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997;89:199-210.
4. Risch A, Ramroth H, Raedts V, Rajaee-Behbahani N, Schmezer P, Bartsch H, Becher H, Dietz A. Laryngeal cancer risk in Caucasians is associated with alcohol and tobacco consumption but not modified by genetic polymorphisms in class I alcohol dehydrogenases ADH1B and ADH1C, and glutathione s-transferases GSTM1 and GSTT1. Pharmacogenetics 2003;13:225-30.
5. Olshan AF, Weissler MC, Watson MA, Bell DA. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2000;9:185-91.
6. Hamel N, Karimi S, Hebert-Bloun MN, Brunet JS, Gilfix B, Ghadiran P, Black MJ, Narod SA, Foulkes WD. Increased risk of head and neck cancer in association with GSTT1 nullizygosity far individuals with low exposure. Int J Cancer 2000;87:452-4.
7. Kietthubthew S, Sriplung H, Au WW. Genetic and environmental interactions on oral cancer in southern Thailand. Environ Mol Mutagen 2001;37:111-6.
8. Rebbeck TR. Molecular epidemiology of the human glutathione S-fransferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-43.
9. Board P, Coggan M, Johnston P Ross V, Suzuki T, Webb G. Genetic heterogeneity of the human glutathione transferase: a complex of gene families. Pharmacol Ther 1990;48:357-49.
10. Sato M, Sato T, Izumo T, Amagasa T. Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis 1999;20:1927-31.
11. Trizna Z, Clayman GL, Spitz MR, Briggs KL, Houston HG. Glutathione S-transferase genotypes as risk factors for head and neck cancer. Am J Surg 1995;170:499-501.
12. Katoh T. Application of molecular biology to occupational health field - the frequency of gene polymorphism of cytochrome P450 1A1 and glutathione S-transferase M1 in patients with lung, oral and urothelial cancer. J UOEH 1995;17:271-8.
13. Deakin M, Elder J, Hendricks C, Peckham D, Baldwin D, Pantin C, Wild N, Leopord P, Bell DA, Jones P, Duncan H, Brannigan K, Alldersea J, Fryer AA, Strange RC. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 1996;17:881-4.
14. Jahnke V, Matthias C, Fryer A, Strange R. Glutathione S-transferase and cytochrome P450 polymorphism as risk factors for squamous cell carcinoma of the larynx. Am J Surg 1996;172:671-3.
15. Hung HC, Chuang J, Chien YC, Chern HD, Chiong CP, Kuo YS. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1: environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev 1997;6:901-5.
16. Park JY, Muscat JE, Ren Q, Schantz SP, Harwick RD, Stem JC. CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev 1997;6:791-7.
17. Oude Ophuis MB, van Lieshout EMM, Roelofs HMJ, Peters WHM, Mannl JJ. Glutathione S-transferase M1 and T1 and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions. Cancer 1998;82:936-43.
18. Coutelle C, Ward PJ, Fleury B, Quattrocchi P, Chambrin H, Iron A, Couzigou P, Cassaigne A. Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Hum Genet 1997;99:319-25.
19. Kihara M Kihara M, Kubota A, Furukawa M, Kimura H. GSTM1 gene polymorphisms as a possible marker for susceptibility to head and neck cancers among Japanese smokers. Cancer Lett 1997;112:257-62.
20. Matthios C, Bockmuhl U, Johnker V, Jones PW, Hayes JD, Alldersea J, Gilford J, Bailey L, Both J, Worral SF, Hand P, Fryer AA, Strange RC. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics 1998;8:91-100.
21. Jourenkova N, Reinikainen M, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev 1998;7:19-23.
22. Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C, Coto E. Genetic polymorphism of N-acetyltransferase-2 glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol 1998;51:294-8.
23. Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M, Kaneko K, Miki H, Fujii T, Yoshino K, Kusuoka H, Monden M. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous cell carcinoma. Int J Cancer 1999;80:685-8.
24. Cheng L, Sturgis EM, Eicher SA, Char D, Spitz MR, Wei Q. Glutathione S-transferase polymorphisms and risk of squamous cell carcinoma of the head and neck. Int J Cancer 1999;84:220-4.
25. Jourenkova-Mironova N, Voho A, Bouchardy C, Wikman H, Dayer P. Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer 1999a;81:44-8.
26. Tanimoto K, Hayashi S, Yoshiga K, Ichikawa T. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol 1999;35:191-6.
27. Katoh T, Kaneko S, Kohshi K, Munaka M, Kitagawa K, Kunugito N Ikemura K, Kawamoto T. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer 1999;83:606-9.
28. Sato M, Sato T, Izumo T, Amagasa T. Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping or CYP1A1 and GSTM1 genes. Oral Oncol 2000;36:267-71.
29. Park JY, Muscat JE, Kaur T, Schantz SP, Stern JC, Richie Jr JP, Lazarus P. Comparison of GSTM polymorphisms and risk for oral cancer between African-Americans and Caucasians. Pharmacogenetics 2000;10:123-31.
30. Hong YJ, Lee JK, Lee GH, Hong S. Influence of glutathione S-transferase M1 and T1 genotypes on larynx cancer risk among Korean smokers. Clin Chem Lab Med 2000;38:917-9.
31. McWilliams JE, Evans AJ, Beer TM, Andersen PE, Cohen JI, Everts EC, Henner WD. Genetic polymorphisms in head and neck cancer risk. Head Neck 2000;22:609-17.
32. Sreelekha TT, Ramadas K, Pandey M, Thomas G, Nalinakumari KR, Pillai MR. Genetic polymorphism of CYP1A1, GSTM1 and GSH1 genes in Indian oral cancer. Oral Oncol 2001;37:593-8.
33. Cabelguenne A, Lariot MA, Stucker I, Blons H, Koum-Besson E, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P, Waziers ID. Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer 2001;93:725-30.
34. Ko Y, Abel J, Harth V, Brode P, Antony C, Donat S, Fischer HP, Ortiz-Pallardo ME, Their R, Sochinidis A, Vetter H, Balt HM, Herberhold C, Bruning T. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001;61:4398-404.
35. Hahn M, Hagedorn G, Kuhlish E, Schackert HK, Eckelt U. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol 2002;38:486-90.
36. Buch S, Notani PN, Bhisey RA. Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis 2002;23:803-7.
37. Ta-Figueras J, Gene M, Gomez-Catalan J, Pique E, Borrego N, Caballero M, Cruellas F, Raya A, Dicenta M, Corbella J. Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in relation to laryngeal carcinoma risk. Cancer Lett 2002;187:95-101.
38. Park JY, Schantz SP, Lazarus P. Epoxide hydralase genotype and oralaryngeal cancer risk: interaction with GSTM1 genotype. Cancer Lett 2003;39:483-90.
39. Cheng YJ, Chien YC, Hildesheim A, Hsu MM, Chen IH, Chuang J, Chang J, Ma YD, Luo CT, Chang JF, Chen Q, Yang CS. No association between genetic polymorphisms of CYP1A1, GSTM1, GSTT1, GSTP1, NAT2, and nasopharyngeal carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev 2003;12:179-80.
40. Gronau S, Koenig-Greger D, Jerg M, Riechelmann H. GSTM1 enzyme concentration and enzyme activity in correlation to the genotype of detoxification enzymes in squamous cell carcinoma of the oral cavity. Oral Dis 2003a;9:62-7.
41. Gronau S, Koenig-Greger D, Jerg M, Riechelmonn H. Genetic polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer? Otolaryngol Head Neck Surg 2003b;128:674-80.
42. Geisler SA, Olshan AF. GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGe review. Am J Epidemiol 2001;154:95-105.
43. Woolf B. On estimating the relationship between blood group and disease. Ann Human Genet 1955;19:251-3.
44. Breslow NE, Day NE. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. Lyon: International Agency for Research an Cancer, 1980;32:134-6.
45. DerSimonian R, Laird N. Meta-analysis in dinical trials. Control Clin Trials 1986;7:177-88.
46. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
47. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomised dinical trials. Stat Med 1991;10:1665-77.
48. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
49. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
50. Egger M, Smith GD. Misleading meta-analysis. BMJ 1995;310:752-4.
51. Schlesselman JJ. Case-control studies, design, conduct, analysis. Oxford: Oxford University Press, 1982:220-6.
52. Jahnke V, Strange R, Matthias C, Fryer A. Glutathione S-transferase and cytochrome P450 genotypes as risk factors for laryngeal carcinoma. Eur Arch Otorhinolaryngol 1997;253(suppl 1):S147-9.
53. Jourenkova-Mironova N, Voho A, Bouchardy C, Wikman H, Dayer P, Benhamou S, Hirvonen A. Glutathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk. Cancer Epidemiol Biomarkers Prev 1999b;8:185-8.
54. Worrall S, Carrigan M, High A, Starr D, Matthias C, Wolf CR, Jones PW, Hand P, Gilford J, Farrell WE, Hoban P, Fryer AA, Strange RC. Susceptibility and outcome in oral cancer preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics 1998;8:433-9.
55. Lafuente A, Pujol F, Carretero P, Villa JP, Cuchi A. Human glutathione S-transferase μ (GSTμ) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett 1993;68:49-54.
56. Lafuente A, Maristany M, Arias C, Cuchi A, Lafuente MJ, Molina R, Bollesto A, Trasserra J. Glutathione and glutathione S-transferase in human squamous cell carcinoma of the larynx and GSTM1 dependent risk. Anticancer Res 1998;18:107-12.
57. Garte S. The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 1998;19:1329-32.
58. Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 2000;10:115-22.
59. Levin ML. The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum 1953;9:531-41.